Semaglutide/NAD+ is the generic form of prescription Wegovy, but half the price.
In a clinical trial, patients who received Semaglutide lost an average of 14.9% of their initial body weight (a loss of about 33 pounds) during the 68-week trial. Those who received a placebo lost only 2.4% of their body weight.
In another, longer trial, patients treated with Semaglutide achieved a 15.2% reduction in body weight at week 104 compared with a 2.6% reduction for those who received placebo.
Our program is half the cost of traditional medication assisted weight loss programs.
Semaglutide/NAD+ is a GLP-1 (glucagon-like peptide 1) receptor agonist medicine and is an injectable prescription medicine used for adults with overweight or obesity to help them lose weight and keep the weight off.
Semaglutide/NAD+ should be used with a reduced calorie meal plan and increased physical activity.
Semaglutide suppresses appetite and regulates insulin.
*Up to 15% of your body weight, on average